NO20072692L - Preparater og fremgangsmater for kort, interfererende nukleinsyreinhibering av Nav1.8 - Google Patents

Preparater og fremgangsmater for kort, interfererende nukleinsyreinhibering av Nav1.8

Info

Publication number
NO20072692L
NO20072692L NO20072692A NO20072692A NO20072692L NO 20072692 L NO20072692 L NO 20072692L NO 20072692 A NO20072692 A NO 20072692A NO 20072692 A NO20072692 A NO 20072692A NO 20072692 L NO20072692 L NO 20072692L
Authority
NO
Norway
Prior art keywords
interfering nucleic
preparations
methods
nucleic acid
short interfering
Prior art date
Application number
NO20072692A
Other languages
English (en)
Inventor
John Hunter
Sameer Goregaoker
Tony Priestley
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of NO20072692L publication Critical patent/NO20072692L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen tilveiebringer korte, interfererende nukleinsyrer, enten enkelttrådede eller dobbelttrådede, som forårsaker RNAiindusert gradering av mRNA fiia Na^l .8-natriumkanalgenet, fannasøytiske preparater som omfatter slike korte, interfererende nukleinsyrer, rekombinante vektorer som omfatter slike korte, interfererende nukleinsyrer, en fremgangsmåte for å inhibere translasjon av et mRNA, en fremgangsmåte for å inhibere uttrykking av et polypeptid, en fremgangsmåte for å blokkere membranpotensialet i en celle, en fremgangsmåte for å blokkere natriumstrømmen i en celle og en fremgangsmåte for å inhibere kronisk smerte.
NO20072692A 2004-10-27 2007-05-25 Preparater og fremgangsmater for kort, interfererende nukleinsyreinhibering av Nav1.8 NO20072692L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62248404P 2004-10-27 2004-10-27
PCT/US2005/038792 WO2006047687A2 (en) 2004-10-27 2005-10-26 Compositions and methods for short interfering nucleic acid inhibition of nav1.8

Publications (1)

Publication Number Publication Date
NO20072692L true NO20072692L (no) 2007-05-25

Family

ID=36061603

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072692A NO20072692L (no) 2004-10-27 2007-05-25 Preparater og fremgangsmater for kort, interfererende nukleinsyreinhibering av Nav1.8

Country Status (14)

Country Link
US (4) US7786291B2 (no)
EP (2) EP1809745A2 (no)
JP (3) JP2008517629A (no)
KR (1) KR20070083828A (no)
CN (2) CN101103112B (no)
AR (1) AR051829A1 (no)
AU (1) AU2005299310A1 (no)
CA (1) CA2584785A1 (no)
IL (1) IL182680A0 (no)
MX (1) MX2007005069A (no)
NO (1) NO20072692L (no)
SG (1) SG158921A1 (no)
WO (1) WO2006047687A2 (no)
ZA (1) ZA200703453B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626584A1 (en) * 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
US8183221B2 (en) 2007-09-05 2012-05-22 Medtronic, Inc. Suppression of SCN9A gene expression and/or function for the treatment of pain
EP2924035A1 (en) 2008-06-30 2015-09-30 Janssen Pharmaceutica NV Substituted pyrimidine derivatives
EP2771335A2 (en) 2011-10-26 2014-09-03 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
TWI516593B (zh) * 2012-06-11 2016-01-11 義守大學 一種聚核苷酸用以製備減緩疼痛藥物之用途
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CA2985347A1 (en) * 2015-05-11 2016-11-17 Alcyone Lifesciences, Inc. Drug delivery systems and methods
CN110022916B (zh) 2016-12-21 2022-06-03 亚克安娜治疗学有限公司 药物递送系统和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513180D0 (en) 1995-06-28 1995-08-30 Univ London Ion channel
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP1272630A2 (en) * 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
AU2001249622B2 (en) * 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
HU230458B1 (hu) * 2000-12-01 2016-07-28 Europäisches Laboratorium für Molekularbiologie (EMBL) Az RNS interferenciát közvetítő kis RNS molekulák
GB0120238D0 (en) 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
US20060030534A1 (en) 2002-09-04 2006-02-09 Gabriele Dorn Treatment of neurological disorders by dsrna administration
WO2004087956A2 (en) 2003-04-02 2004-10-14 Ionix Pharmaceuticals Limited Cell lines for the functional expression of nav1.8
DK3604537T3 (da) 2003-06-13 2022-02-28 Alnylam Europe Ag Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
US7341835B2 (en) * 2004-01-13 2008-03-11 Affymetrix, Inc. Methods of analysis of alternative splicing in mouse

Also Published As

Publication number Publication date
US20100305192A1 (en) 2010-12-02
CN101103112B (zh) 2011-11-16
CA2584785A1 (en) 2006-05-04
US8729045B2 (en) 2014-05-20
US20130109739A1 (en) 2013-05-02
AR051829A1 (es) 2007-02-14
WO2006047687A2 (en) 2006-05-04
US20140256787A1 (en) 2014-09-11
IL182680A0 (en) 2007-09-20
MX2007005069A (es) 2007-06-25
WO2006047687A3 (en) 2006-07-06
CN102352355A (zh) 2012-02-15
JP2011015695A (ja) 2011-01-27
US20060199779A1 (en) 2006-09-07
EP2371954A1 (en) 2011-10-05
JP2008517629A (ja) 2008-05-29
CN101103112A (zh) 2008-01-09
JP2013176386A (ja) 2013-09-09
KR20070083828A (ko) 2007-08-24
ZA200703453B (en) 2008-06-25
EP1809745A2 (en) 2007-07-25
US7786291B2 (en) 2010-08-31
US8309703B2 (en) 2012-11-13
SG158921A1 (en) 2010-02-26
AU2005299310A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
NO20072692L (no) Preparater og fremgangsmater for kort, interfererende nukleinsyreinhibering av Nav1.8
Cai et al. PROTON GRADIENT REGULATION 3 recognizes multiple targets with limited similarity and mediates translation and RNA stabilization in plastids
AR066338A1 (es) Proteinas toxinas activas contra hemipteros y coleopteros de bacillus thuringiensis
BRPI0413521A (pt) seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares
BRPI0706266A2 (pt) mÉtodos para controle de pragas usando a rnai
ATE494370T1 (de) Vektoren auf transposonbasis und verfahren zur integration von nukleinsäuren
WO2005117991A3 (en) Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
ATE513910T1 (de) Methoden zur gensuppression mithilfe von rnai verstärkenden faktoren
BR9812540A (pt) Expressão de genes endógenos por recombinaçãonão homóloga de uma construção de vetor comdna celular
WO2006131599A3 (en) Method of profiling a cell population
BRPI0410876A (pt) molécula inibidora do complemento, anticorpo, proteìna de fusão, molécula de ácido nucleico, vetor, célula hospedeira, métodos para preparar uma molécula inibidora do complemento ou um seu equivalente funcional ou uma proteìna de fusão, para identificar um ligando de uma molécula inibidora do complemento, ou um seu equivalente funcional, para tratar um animal que esteja sofrendo de uma doença ou um distúrbio mediados pelo complemento, ou prevenir que um aninal desenvolva uma doença ou um disturbio mediados pelo complemento, para vacinar um animal contra uma doença ou um distúrbio transmitidos por um artrópode hematófago e para inibir as vias do complemento clássica e alternativa em uma célula, tecido ou organismo não humano, composição, uso de uma molécula inibidora do complemento, uma proteìna de fusão ou uma molécula de ácido nucleico
WO2005042692A3 (en) A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
BRPI0415302A (pt) uso de polimorfismos genéticos que se associam a eficácia de tratamento de doença inflamatória
WO2004111608A8 (en) Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
WO2008054341A3 (en) Method of bioimaging using nanocrystals of fluorescent dyes
WO2005012489A3 (en) Targeting endothelium for tissue-specific delivery of agents
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
Reiber et al. The expression of selected non-ribosomal peptide synthetases in Aspergillus fumigatus is controlled by the availability of free iron
WO2004022782A3 (en) Compositions and methods for tissue specific or inducible inhibition of gene expression
WO2005089426A3 (en) Method of treating sepsis
WO2006116380A3 (en) Plasma or serum fraction for the treatment or prevention of bacterial infections
Weatherly et al. Intermediate-depth circulation in the Gulf of Mexico estimated from direct measurements
WO2009116984A3 (en) Highly thermostable fluorescent proteins
WO2008144351A3 (en) Compositions and methods for inhibiting inducible t cell kinase (itk) and treating asthma and bronchial inflammations
ATE486127T1 (de) Wiederherstellung der aktivität von 5- enolpyruvylshikimat-3-phosphat-synthase durch fragmentkomplementierung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application